PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Emmanuel S. Antonarakis, MD - Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications
Go online to PeerView.com/JEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Emmanuel S. Antonarakis, MD, discusses the rationale for targeting DNA repair defects through PARP inhibition and reviews recent safety and efficacy evidence with PARP inhibitors in patients with prostate cancer. He also highlights guidelines for genetic testing that is used to identify patients who might benefit from PARP inhibitor therapy and explores using PARP inhibitors in the urology clinic. Upon completion of this activity, participants should be better able to: Describe the rationale for therapeutic targeting of DNA repair defects and the mechanism of PARP inhibition in managing BRCA-mutant prostate cancer, Review companion diagnostic tests that detect germline and somatic mutations within the DNA repair pathways, Discuss the latest evidence with PARP inhibitors in advanced prostate cancer harboring DNA repair defects, Identify patients with prostate cancer who may be candidates for clinical trial based therapeutic approaches, including studies testing combination regimens with PARP inhibitor components.